Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with PD; SLS-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; SLS-004 for the treatment of PD; SLS-010, an oral histamine H3A receptor antagonist for narcolepsy and related disorders; and SLS-012, an injectable therapy for post-operative pain management. Seelos Therapeutics, Inc. was incorporated in 1987 and is headquartered in New York, New York.
Revenue of Seelos Therapeutics, Inc. (SEEL)
Revenue in 2023 (TTM): $2.2 M
According to Seelos Therapeutics, Inc.'s latest financial reports the company's current revenue (TTM) is $2.2 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Seelos Therapeutics, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $2.2 M | $-27,914,000 | $-37,750,000 | $-37,882,000 | $-37,882,000 |
| 2022 | $ | $-53,000 | $-73,467,000 | $-73,534,000 | $-76,138,000 |
| 2021 | $ | $ | $ | $-66,048,000 | $-67,533,000 |
| 2020 | $ | $ | $ | $-19,101,000 | $-19,220,000 |
| 2019 | $375 K | $-22,188,000 | $-29,330,000 | $-50,880,000 | $-50,383,000 |
| 2018 | $ | $ | $-3,143,000 | $-9,218,000 | $-9,242,000 |
| 2017 | $ | $-117,000 | $-10,556,000 | $-11,749,000 | $321 K |
| 2016 | $5.76 M | $1.87 M | $-6,108,999 | $-7,433,000 | $-7,433,000 |
| 2015 | $4.84 M | $3.92 M | $-17,828,000 | $-19,023,000 | $-19,023,000 |
| 2014 | $9.26 M | $8.34 M | $-21,968,000 | $-22,477,000 | $-21,786,000 |
| 2013 | $2.51 M | $-120,000 | $-15,066,000 | $-15,870,000 | $-16,938,000 |
| 2012 | $8.42 M | $3.86 M | $-24,516,000 | $-25,044,000 | $-31,771,000 |
| 2011 | $4.1 M | $1.86 M | $-17,137,953 | $-18,117,198 | $-18,117,198 |
| 2010 | $4.97 M | $1.03 M | $-19,975,450 | $-29,508,346 | $-29,508,346 |
| 2009 | $2.97 M | $2.85 M | $-3,396,643 | $-32,480,356 | $-32,042,562 |
| 2008 | $5.96 M | $5.96 M | $-4,615,639 | $-6,108,855 | $-5,171,198 |
| 2007 | $1.27 M | $1.27 M | $-8,356,376 | $-9,593,137 | $-8,787,228 |
| 2006 | $1.87 M | $1.87 M | $-7,958,838 | $-8,610,650 | $-8,043,253 |
| 2005 | $2.4 M | $2.4 M | $-14,432,710 | $-15,923,554 | $-15,442,438 |
| 2004 | $359.37 K | $359.37 K | $-16,141,528 | $-17,562,695 | $-17,023,648 |
| 2003 | $110.74 K | $110.74 K | $-12,978,499 | $-17,465,797 | $-17,233,864 |
| 2002 | $148.03 K | $121 K | $-26,493,700 | $-27,884,164 | $-27,641,519 |
| 2001 | $68.09 K | $23.04 K | $-16,676,356 | $-17,378,152 | $-16,174,861 |
| 2000 | $1 | $257.15 K | $-9,844,598 | $-9,976,002 | $-8,830,071 |
| 1999 | $1.5 M | $200 K | $-4,002,698 | $-2,300,000 | $-2,500,000 |
| 1998 | $5.71 M | $522.78 K | $-4,073,270 | $ | $-4,779,002 |
| 1997 | $56.18 K | $56.18 K | $-3,815,515 | $ | $-3,857,466 |